Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)

NCT ID: NCT01876992

Last Updated: 2017-09-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-01-31
• Study Completion Date: 2015-06-30

Brief Summary

The investigators know that metformin works at the level of the cells in the body by acting on a protein called Cyclic amine monophosphate- Response Binding Elements (CREB) binding protein or Constitutive Reverter of eIF2α Phosphorylation (CREP) Binding Protein (CBP). What the investigators do not know is how this process is affected when the dose of the metformin is increased or changed.

Currently the same doses of metformin are often used in both children and adults, but it is possible that the dose of metformin should be based on age and weight. Understanding how CBP works could potentially help us to tailor metformin treatment individually for patients based on their age, weight and CBP response.

Detailed Description

Our studies have shown that metformin acts at the cellular level by acting on a target protein, Cyclic amine monophosphate-Response Binding Elements (CREB) binding protein or CREP Binding Protein (CBP). Patients are treated with many different doses of metformin, some patients respond well to low doses while others require much higher doses. The investigators do not understand why this may be and are interested in knowing if the investigators can treat patents effectively with low doses. What the investigators do not know is how this process is affected when the dose of the metformin is increased or changed. Changes in metformin's target protein will provide evidence on the effectiveness of the dose.

Also, currently the same doses of metformin are often used in both children and adults, but it is possible that the dose of metformin should be based on age and weight. Understanding how CBP works could potentially help us to tailor metformin treatment individually for patients based on their age, weight and CBP response.

Conditions

Diabetes; Pre-diabetes; Obesity

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Metformin

Doses will be increased incrementally. Decisions to escalate the metformin dose will be made based upon tolerability of side effects as described in the schedule of evaluations to follow. All subjects will be monitored for safety while receiving metformin. Any participant with blood glucose of <60mg/dl at any time while receiving metformin will have therapy stopped and will be withdrawn from the study.

For children <50kg:

Baseline:250mg po qd, Week 2:250mg po bid, Week 4:500mg po am/250mg po pm, Week 8:500mg po bid.

For children ≥50kg:

Baseline:500mg po qd, Week 2:500mg po bid, Week 4:1000mg po am/500mg po pm, Week 8:1000mg po bid.

For adults:

Baseline:500mg po qd,Week2:500mg po bid,Week 4:1000mg po am/500mg po pm,Week 8:1000mg po bid.

Group Type: EXPERIMENTAL

Metformin

Intervention Type: DRUG

Obese Controls

Three obese but otherwise healthy adult participants will be recruited into the study as controls. These will be individuals who are not currently (or previously) on any diabetic medication including metformin.

There will be a single study visit and no medication will be administered. They will be administered a meal and pre and post-prandial blood samples will be drawn.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Metformin

Intervention Type: DRUG

Other Intervention Names

Glucophage, Fortamet

Eligibility Criteria

Inclusion Criteria

• Children 10-17 years.
• Both genders (male and female)
• All children must have a Primary Care Physician and/or an Endocrinologist who must be aware that the child under their care will be part of the study.
• All children must have a Primary Care Physician and/or an Endocrinologist who is considering initiating metformin therapy now or in the near future as part of standard clinical care.
• Naïve to metformin.
• Either: Prediabetic children Or diabetic children under good glycemic control

• Adults 18-79 years
• Both genders (male and female)
• All participants must have a Primary Care Physician and/or an Endocrinologist who must be aware that the adult under their care will be part of the study
• All participants must have a Primary Care Physician and/or an Endocrinologist who is considering initiating metformin therapy now or in the near future as part of standard clinical care.
• Naive to metformin
• EITHER: Prediabetic adults OR diabetic adults, under fair glycemic control:

• Age 18-79
• Both genders (male and female)
• BMI > 30 kg/m2

Exclusion Criteria

• Children ages 10-17 who do not have parental consent and/or do not give assent
• Children living in foster care
• Children with allergies to foods in the breakfast menu
• Children who currently consume any alcohol
• Children on current antidiabetic medication or those who have been on any antidiabetic medication in the 3 months prior to enrolment
• Children with a history of /or concurrent chronic disease (eg. heart, kidney, liver disease or any type of malignancy or pre-malignant condition) that required hospitalization within the last 6 months
• Pregnancy
• Refusal by a female participant who is of child bearing potential and sexually active to use contraceptive methods such as oral contraceptive pills, barrier methods and abstinence
• Children weighing less than 36 kg
• Children with any condition that increases the risk of lactic acidosis (e.g. cancer, infection, congestive heart failure, renal disease )
• Children with history of recent hospitalization for surgery, dehydration, sepsis, hypoxemia (within the past 6 months)
• Children with history of weight loss, polyuria and polydipsia
• Children who are currently enrolled in a weight management program
• Children with known hypersensitivity to metformin
• Children with a fasting blood glucose of >180mg/dl
• Children with a HbA1c level of ≥7%
• Children with glycosuria
• Children with clinical or laboratory evidence of hepatic disease- transaminase levels three times the upper normal range (Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)) and/or a increased level of Gamma-glutamyltransferase (GGT), Prothrombin Time (PT), International Normalized Ratio (INR) from the reference normal range and a serum albumin less than the reference normal range of the Johns Hopkins Clinical Laboratories.
• If iodinated contrast is used on a participant, due to possible acute alteration of renal function resulting in increased risk of lactic acidosis, the participant will be excluded.
• Children with renal impairment

• In children >50kg, renal impairment is defined by a serum creatinine 1.4 mg/dl or higher in females or 1.5mg/dl or higher in males OR estimated Glomerular Filtration Rates (eGFR) ≤60mL/min by the Schwartz formula.
• In children <50kg, renal impairment is defined by eGFR <100 mL/min by the Schwartz formula.
• Children with acid-base disturbance as defined by serum bicarbonate levels less than 20mEq/L or greater than 29mEq/L.

• Pregnancy
• Adults who are not able to understand the Informed Consent document and who are unwilling to do the study
• Adults with allergies to any of the foods in the breakfast menu
• Adults on current antidiabetic medication or on any antidiabetic medication in the 3 months prior to enrolment.
• Adults with a history of /or concurrent chronic disease (e.g. heart, kidney, liver disease or any type of malignancy or pre-malignant condition) that required hospitalization within the last 6 months
• Refusal by a female participant who is of child bearing potential and sexually active to use contraceptive methods such as oral contraceptive pills, barrier methods and abstinence
• Adults with excessive current intake of alcohol (>2 drinks/day for males and >1 drink/day for females)
• Adults who have engaged in binge drinking (>5 drinks within a 2 hour period) in the last 3 months
• Adults with history of recent hospitalization for surgery, dehydration, sepsis, hypoxemia (past 6 months)
• Hypersensitivity to metformin.
• Adults with fasting blood glucose of >180mg/dl.
• Adults with HbA1c level of ≥8%
• Adults with glycosuria.
• Adults with any condition that increases the risk of lactic acidosis (e.g. cancer, infection, congestive heart failure, renal disease )
• Adults with clinical or laboratory evidence of hepatic disease- transaminase levels three times the upper normal range (AST and ALT) and/or a increased level of GGT, PT, INR from the reference normal range and a serum albumin less than the reference normal range of the Johns Hopkins Clinical Laboratories.
• If iodinated contrast is used on a participant, due to possible acute alteration of renal function resulting in increased risk of lactic acidosis, the adult participant will be excluded.
• Adults with renal impairment as defined by a serum creatinine 1.4 mg/dl or higher in females or 1.5mg/dl or higher in males OR estimated Glomerular Filtration Rates (eGFR) ≤60mL/min by Modification of Diet in Renal Disease (MDRD) formula.
• Adults with acid-base disturbance as defined as serum bicarbonate levels less than 20mEq/L or greater than 29mEq/L.

• Subjects previously or currently on any diabetes medication, including metformin, will be excluded.
• Pregnancy
• Subjects with history of or concurrent chronic disease (e.g. heart, kidney, liver disease or any type of malignancy or pre-malignant condition) that required hospitalization within the last 6 months will be excluded.
• Adults with allergies to any of the foods in the breakfast menu
• Adults with excessive current intake of alcohol (>2 drinks/day for males and >1 drink/day for females)
• Adults who have engaged in binge drinking (>5 drinks within a 2 hour period) in the last 3 months

• Minimum Eligible Age: 10 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sally Radovick, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University Department of Medicine

Locations

Johns Hopkins University

Baltimore, Maryland, United States

Countries

United States

Other Identifiers

NA_00046072

Identifier Type: OTHER

Identifier Source: secondary_id

NA_00046072

Identifier Type: -

Identifier Source: org_study_id